Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012

Description: Central Nervous System (CNS) Tumor – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central Nervous System (CNS) Tumor. Central Nervous System (CNS) Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Central Nervous System (CNS) Tumor.
- A review of the Central Nervous System (CNS) Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Central Nervous System (CNS) Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Central Nervous System (CNS) Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Central Nervous System (CNS) Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 6
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Central Nervous System (CNS) Tumor Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Central Nervous System (CNS) Tumor 12
Central Nervous System (CNS) Tumor Therapeutics under Development by Companies 14
Central Nervous System (CNS) Tumor Therapeutics under Investigation by Universities/Institutes 21
Stemline Therapeutics, Inc. 113
APEIRON Biologics AG 114
Cellceutix Corporation 115
TVAX Biomedical, LLC 116
to-BBB technologies BV 117
Targepeutics, Inc. 118
Lipopharma 119
Kringle Pharma, Inc. 120
Archer Biosciences, Inc 121
Galaxy Biotech, LLC 122
ipal GmbH 123
PepTx, Inc. 124
Errant Gene Therapeutics, LLC 125
TAU Therapeutics, LLC 126
EirGen Pharma Ltd. 127
CellAct Pharma GmbH 128
Tocagen Inc 129
Central Nervous System (CNS) Tumor – Therapeutics Assessment 130
Assessment by Monotherapy Products 130
Assessment by Combination Products 131
Drug Profiles 132
Antineoplaston A-10 + Antineoplaston AS2-1 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
trabedersen - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
nimotuzumab - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
Theracim + Radiation Therapy - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Radiation Therapy + Procarbazine + ACNU - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Radiation Therapy + ACNU - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Temozolomide + Etoposide + Trofosfamid - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 149
List of Tables
Number of Products Under Development for Central Nervous System (CNS) Tumor, H2 2012 12
Products under Development for Central Nervous System (CNS) Tumor – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Development by Companies, H2 2012 (Contd..2) 17
Number of Products under Development by Companies, H2 2012 (Contd..3) 18
Number of Products under Development by Companies, H2 2012 (Contd..4) 19
Number of Products under Development by Companies, H2 2012 (Contd..5) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Development by Companies, H2 2012 (Contd..4) 38
Products under Development by Companies, H2 2012 (Contd..5) 39
Products under Development by Companies, H2 2012 (Contd..6) 40
Products under Investigation by Universities/Institutes, H2 2012 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 61
Genzyme Corporation, H2 2012 62
F. Hoffmann-La Roche Ltd., H2 2012 63
Vical Incorporated, H2 2012 64
United Therapeutics Corporation, H2 2012 65
Amgen Inc., H2 2012 66
Sanofi-Aventis, H2 2012 67
Eli Lilly and Company, H2 2012 68
Viralytics Ltd., H2 2012 69
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 130
Assessment by Combination Products, H2 2012 131

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2366353/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Central Nervous System (CNS) Tumor - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2366353/
Office Code: SCD2I6L4

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
[ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World